Patent · US Expired

HLA-restricted hepatitis B virus CTL epitopes

US6322789A · kind A · utility

22Cited by
15References
22Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 5, 1995
Grant dateNov 27, 2001
Priority date—
Expiry dateJun 5, 2015

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2730/10122
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Cytotoxic T lymphocyte-stimulating peptides induce HLA-restricted responses to hepatitis B virus antigens. The peptides, derived from CTL epitopic regions of both HBV surface and nucleocapsid antigens, are particularly useful in the treatment and prevention of HBV infection, including the treatment of chronically infected HBV carriers. The peptides can be formulated as HBV vaccines and pharmaceutical compositions, such as lipid-containing compositions for enhancing the HLA-restricted CTL responses. The peptides are also useful in diagnostic methods, such as predicting which HBV-infected individuals are prone to developing chronic infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.